The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Atrial fibrillation was diagnosed in 477 of 1,501 (31.8%) participants in the monitoring group and 550 of 4,503 (12.2%) participants in the control group (HR 3.17, 95% CI 2.81-3.59, P<0.001), reported ...

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Please provide your email address to receive an email when new articles are posted on . Continuous implantable loop recorder monitoring resulted in a threefold increase in atrial fibrillation ...

Using an implantable loop recorder (ILR) to screen older individuals for atrial fibrillation (AF) may be more beneficial when NT-proBNP levels are high, according to a post hoc analysis of the LOOP ...